drugset / Trial / NCT02141711

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

NCT02141711

Phase 1 Completed 48 enrolled Takeda
RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.

Timeline

Start
2008-10
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 10 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral
Subject Vonoprazan Other / unclassified 30 mg Oral
Subject Vonoprazan Other / unclassified 40 mg Oral